By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom today said that it has entered into a three-year supply agreement with Illumina for sequencing equipment and consumables.

Sequenom and its subsidiaries will purchase the Illumina products for use in developing its non-invasive trisomy 21 test. In addition, the firms intend to work collaboratively toward the submission of regulatory clearance of an in vitro diagnostic test for detecting fetal chromosomal abnormalities.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.